Lanreotide Autogel/Depot (LAN) in Combination with Peptide Receptor Radionuclide Therapy (PRRT) in Progressive Digestive and Lung Neuroendocrine Tumours (NETs): Design of the PRELUDE Study

#1808

Introduction: PRRT has potential to control progressive NETs and has been used in combination with somatostatin analogues such as LAN.

Aim(s): To investigate effects of PRRT in combination with LAN (LAN–PRRT) in pts with progressive gastroenteropancreatic (GEP)- and lung NETs.

Materials and methods: This retrospective study will analyse existing records to describe LAN–PRRT in 150 pts from 5 countries (NCT02788578). Key inclusion criteria are adults with progressive, metastatic well-differentiated GEP- or lung NETs, evaluable imaging ≤6mo and ≤12mo before first LAN–PRRT cycle and at end of last cycle, positive SSTR status, ECOG PS0–1, ≥1 LAN injection in 8wks prior to first LAN–PRRT cycle, no prior PRRT, continuous LAN in all cycles, and total cumulative activity of ≥500mCi of 177Lu-DOTATOC or 177Lu-DOTATATE.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Prasad V, Truong Thanh X, Houchard A, Bodei L,

Keywords: PRRT, lanreotide,